Publications by authors named "Philipp Mann"

Claim this Profile
E
Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial.
Susan P Buchbinder, Sabrina Spinosa Guzman, Jorge Sanchez, Wouter Willems, Daniel J Stieh, Philipp Mann

Lancet HIV· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics Analysis of Serum and Rectal Tissue Concentrations of a Pair of Anti-HIV Monoclonal Antibodies, VRC01 and VRC01LS, in Adults Without HIV.
Yunda Huang, Lily Zhang, Maria P Lemos, Rena D Astronomo, Sandeep Narpala, Philipp Mann

J Clin Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
Brandon J Essink, Craig Shapiro, Marie Grace Dawn Isidro, Paul Bradley, Antoinette Pragalos, Claudia Hoffmann, Philipp Mann

Hum Vaccin Immunother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer.
Pierre-Antoine Bannier, Charlie Saillard, Philipp Mann, Maxime Touzot, Charles Maussion, Arndt Hartmann

Nat Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.
Glenda E Gray, Kathryn Mngadi, Ludo Lavreys, Steven Nijs, Peter B Gilbert, Philipp Mann

Lancet Infect Dis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced and sustained biodistribution of HIV-1 neutralizing antibody VRC01LS in human genital and rectal mucosa.
Maria P Lemos, Rena D Astronomo, Yunda Huang, Sandeep Narpala, Madhu Prabhakaran, Philipp Mann

Nat Commun· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial.
Nigel Garrett, One Dintwe, Cynthia L Monaco, Megan Jones, Kelly E Seaton, Philipp Mann

J Acquir Immune Defic Syndr· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3, randomised, observer-blinded, placebo controlled-trial evaluating the safety and immunogenicity of investigational SARS-CoV-2 mRNA vaccine CVnCoV in adult healthcare workers in Mainz (Germany).
Frank Kowalzik, Daniel Teschner, Margarida Mesquita, Christian Jensen, Daniel Schreiner, Philipp Mann

Vaccine X· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity.
Olaf-Oliver Wolz, Dominik Vahrenhorst, Gianluca Quintini, Christina Lemberg, Sven D Koch, Philipp Mann

Vaccines (Basel)· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of complex radiotherapy techniques using polymer gel dosimetry.
Christian P Karger, Alina Elter, Stefan Dorsch, Philipp Mann, Evangelos Pappas

Phys Med Biol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study" [Vaccine: X 11 (2022) 100189].
Xavier Sáez-Llorens, Claudio Lanata, Elaine Aranguren, Carlos R Celis, Rubelio Cornejo, Philipp Mann

Vaccine X· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study.
Daniel J Stieh, Dan H Barouch, Christy Comeaux, Michal Sarnecki, Kathryn E Stephenson, Philipp Mann

J Infect Dis· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study.
Xavier Sáez-Llorens, Claudio Lanata, Elaine Aranguren, Carlos R Celis, Rubelio Cornejo, Philipp Mann

Vaccine X· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
Peter G Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana-Arri, Gustavo Jose Aroca Martinez, Marc Bonten, Clara Lehmann, Philipp Mann

Lancet Infect Dis· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant.
Olaf-Oliver Wolz, Sarah-Katharina Kays, Helga Junker, Sven D Koch, Philipp Mann

Vaccines (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Technical Note: On the feasibility of performing dosimetry in target and organ at risk using polymer dosimetry gel and thermoluminescence detectors in an anthropomorphic, deformable, and multimodal pelvis phantom.
Mathieu Marot, Alina Elter, Philipp Mann, Andrea Schwahofer, Clemens Lang, Bettina Beuthien-Baumann, Clarissa Gillmann

Med Phys· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial.
Peter G Kremsner, Philipp Mann, Arne Kroidl, Isabel Leroux-Roels, Christoph Schindler

Wien Klin Wochenschr· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Technical Note: ADAM PETer - An anthropomorphic, deformable and multimodality pelvis phantom with positron emission tomography extension for radiotherapy.
Clarissa Gillmann, Noa Homolka, Wibke Johnen, Armin Runz, Gernot Echner, Philipp Mann, Aswin L Hoffmann, Bettina Beuthien-Baumann

Med Phys· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein.
Mina C Hosseinipour, Craig Innes, Sarita Naidoo, Philipp Mann, Julia Hutter

Clin Infect Dis· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
Lindsey R Baden, Daniel J Stieh, Michal Sarnecki, Stephen R Walsh, Georgia D Tomaras, Philipp Mann, Frank Wegmann

Lancet HIV· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
Zoe Moodie, Stephen R Walsh, Fatima Laher, Lucas Maganga, Michael E Herce, Philipp Mann

PLoS Med· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.
Edna O Viegas, Arne Kroidl, Patricia J Munseri, Marco Missanga, Charlotta Nilsson, Philipp Mann

PLoS One· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.
Julie A Ake, Alexandra Schuetz, Poonam Pegu, Lindsay Wieczorek, Michael A Eller, Philipp Mann

J Infect Dis· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRI.
Thorsten Heußer, Philipp Mann, Christopher M Rank, Martin Schäfer, Antonia Dimitrakopoulou-Strauss

PLoS One· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
Asli Bauer, Lilli Podola, Philipp Mann, Marco Missanga, Antelmo Haule

J Virol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis